Loading Events

Past Events › Grant

Events Search and Views Navigation

Event Views Navigation

July 2019

NIH Cycles R01 and U01

July 5, 2019
|Recurring Event (See all)

One event on March 5, 2019 at 12:00 am

One event on November 5, 2019 at 12:00 am

NINDS Exploratory Clinical Trials (U01)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
NINDS Efficacy Clinical Trials (U01)
he purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for  investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS) to establish the efficacy (or compare the effectiveness) of treatment interventions. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Promoting Research in Basic Neuroscience (R01)
The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Prevention Research in Mid-Life Adults (R01)
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Pregnancy in Woman with Disabilities (R01)
Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Application budgets are not limited but need to reflect the actual needs of the proposed project.

 

Find out more »

Cycle 3: Alzheimer’s Drug Discovery Foundation

July 12, 2019

LOI DUE JULY 12, 2019
Drug Discovery Program
Seeks to fund promising preclinical drug discovery and biomarker development programs for Alzheimer’s disease, related dementias and cognitive aging. The ADDF typically supports one year of research at a time, with potential for future follow-on funding. Funding can range from $150,000-$600,000 for a preclinical project.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. The average award is up to $5 million based on stage and scope of research. Depending on the availability of funds, in certain cases, well-justified larger budgets may be considered.
Biomarkers Development
This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Awards range between $50,000-$100,000 for epidemiological analyses based on scope of research, and can reach up to $3 million for clinical trials based on stage and scope of research.

Find out more »

August 2019

ASGCT Career Development Awards

August 1, 2019

Sponsor: American Society for Cell and Gene Therapy
Application Due Date: August 1, 2019
Awards and Eligibility: ASGCT will award a $50,000 Career Development Award to support independent transformative pilot studies in gene and cell therapy by ASGCT members, particularly those ideas that would be challenging to fund with normal funding mechanisms.

Find out more »

September 2019

Cycle 1: NIH R41, R42, R43, R44, U43, U44

September 5, 2019

 

DUE DATE: SEPTEMBER 5, 2019

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

October 2019

Cycle 3: Whitehall Foundation Grants-in-Aids

October 1, 2019

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: October 1, 2019
Application Due Date: February 15, 2020
Award:  Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.

Find out more »

Cycle 3: Whitehall Foundation Research Grants

October 1, 2019

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: October 1, 2019
Application Due Date: February 15, 2020
Award: Research grants normally range from $30,000 to $75,000 per year for up to three years.

Find out more »

AES Research and Training Workshops

October 1, 2019
|Recurring Event (See all)

One event on October 1, 2019 at 12:00 am

Sponsor: American Epilepsy Society
Due Date: April 15, 2019 or October 1, 2019
Award: AES welcomes applications for funding to support scientific conferences and workshops focused on epilepsy research and training. Applications for workshop funding are reviewed by the AES Research and Training Council, and the number and amount of awards made each year are contingent on available funds.

Find out more »

Molecular Mechanisms of Blood-Brain Barrier Function and Dysfunction in Alzheimer’s disease and Alzheimer’s related dementias (AD/ADRD) (R01 Clinical Trial Not Allowed)

October 9, 2019

Sponsor: NIH
LOI Due Date: September 9, 2019
Application Deadline: October 9, 2019
Description:The goal of this initiative is to elucidate the mechanistic links between blood brain barrier (BBB) dysfunction, Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD), and how related comorbidities impact the basic molecular mechanisms of BBB health and function.
Award: Application budgets are limited to $499,000 direct costs/year and need to reflect the actual needs of the proposed project.

Find out more »

Cycle 4: Alzheimer’s Drug Discovery Foundation

October 11, 2019

LOI DUE OCTOBER 11, 2019
Drug Discovery Program
The Drug Discovery RFP supports novel drug programs and repurposed/repositioned programs. One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. The average award is up to $5 million based on stage and scope of research. Depending on the availability of funds, in certain cases, well-justified larger budgets may be considered.
Biomarkers Development
This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Awards range between $50,000-$100,000 for epidemiological analyses based on scope of research, and can reach up to $3 million for clinical trials based on stage and scope of research.

Find out more »

Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)

October 28, 2019

Sponsor: NIH Common Fund Program
LOI Due Date: September 28, 2019
Application Deadline: October 28, 2019
Details: The goal of this funding opportunity announcement (FOA) for the Common Fund Program “Illuminating the Druggable Genome” (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.
Award:  Application budgets are limited to $100,000 in direct costs (excluding subcontract F&A) for one year and need to reflect the actual needs of the proposed project.

Find out more »

November 2019

American Fellowships: Summer/Short-Term Research Publication Grants

November 1, 2019

Sponsor: American Association of University Women Educational Foundation
Due Date: November 1, 2019
Award: $6,000 is available for an eight-week grant period.

Find out more »

Cycle 3: Prevention Research in Mid-Life Adults (R01)

November 5, 2019

Sponsor: National Institutes of Health
Due Date: November 5, 2019 by 5 pm local time of applicant
Award: Money, property, or both to carry out an approved project or activity. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The maximum grant period is five years.

Find out more »

NIH Cycles R01 and U01

November 5, 2019
|Recurring Event (See all)

One event on March 5, 2019 at 12:00 am

One event on November 5, 2019 at 12:00 am

NINDS Exploratory Clinical Trials (U01)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
NINDS Efficacy Clinical Trials (U01)
he purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for  investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS) to establish the efficacy (or compare the effectiveness) of treatment interventions. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Promoting Research in Basic Neuroscience (R01)
The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Prevention Research in Mid-Life Adults (R01)
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. Budgets must reflect the actual needs; maximum request cannot exceed 5 years.
Pregnancy in Woman with Disabilities (R01)
Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Application budgets are not limited but need to reflect the actual needs of the proposed project.

 

Find out more »

January 2020

Cycle 1: Whitehall Foundation Grants-In-Aid

January 1

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Grants-in-Aid are awarded for a one-year period and do not exceed $30,000.

Find out more »

Healthcare Research by Community Physicians

January 1

Sponsor: Physicans’ Services Incorporated Foundation

Due Date: Applications accepted on a rolling basis

Award: Grants up to $20,000 are available to cover the costs of the data gathering and analysis,
support staff and preparation of reports. Up to an additional $500 will be provided for travel
costs incurred in presenting papers on the results of a community practice study.

 

Find out more »

Cycle 2: NIH R41, R42, R43, R44, U43, U44

January 5

DUE DATE: JANUARY 5, 2020

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »

Cycle 1: Whitehall Foundation Research Grants

January 15

Sponsor: Whitehall Foundation, Inc.
LOI Due Date: January 15, 2020
Application Due Date: June 1, 2020
Award: Research grants normally range from $30,000 to $75,000 per year for up to three years.

Find out more »

February 2020

NIH R01 Cycles

February 5
|Recurring Event (See all)

One event on June 5, 2020 at 12:00 am

One event on October 5, 2020 at 12:00 am

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional):
The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. Application budgets are not limited but need to reflect the actual needs of the proposed project.

High Throughput Screening (HTS) to Discover Chemical Probes:
Encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities:
Encourages applications from institutions/ organizations addressing preclinical research in model organisms of neurodevelopmental disorders. Budgets for direct costs of up to $499,999 per year may be requested.

Pregnancy in Women with Disabilities:
This FOA issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grants (R01) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional):
This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and well-being as individuals age and prevent illness and disability in later years.Application budgets are not limited but need to reflect the actual needs of the proposed project.

Promoting Research in Basic Neuroscience (R01 Clinical Trial Not Allowed):
he goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Find out more »

March 2020

AES Seed Grant Program 

March 23
|Recurring Event (See all)

One event on March 23, 2020 at 12:00 am

Sponsor: American Epilepsy Society
Due Date: September 22, 2019 or March 23, 2020
Award: The AES Seed Grant Program provides support to established investigators to pursue new and innovative directions in epilepsy research, bring new research methods to their research programs, or begin new collaborations with other investigators in epilepsy or in different, complementary disciplines. Seed Grants may provide up to $20,000 for one year for direct costs only, and they may not be renewed.

Find out more »

April 2020

Cycle 3: NIH R41, R42, R43, R44, U43, U44

April 5

DUE DATE: APRIL 5, 2020

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR)(R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) which uses the STTR grant mechanism, will support to support the development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits- a major goal of the BRAIN Initiative. This FOA will support further development of neurotechnologies developed through the BRAIN initiative or through other funding programs in preparation for commercial dissemination. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics.

BRAIN Initiative: Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR)(R41/R42 Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II).

Find out more »
+ Export Events